{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:13:56Z","timestamp":1791465236883,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Government ivory","award":["none"],"award-info":[{"award-number":["none"]}]},{"name":"Canceroloe CLARA","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Alterations in estrogen and progesterone signaling, via their respective receptors, estrogen receptor alpha (ER\u03b1) and progesterone receptor (PR), respectively, are largely involved in the development of breast cancer (BC). The recent identification of ER\u03b1-36, a splice variant of ER\u03b1, has uncovered a new facet of this pathology. Although ER\u03b1-36 expression is associated with poor prognosis, metastasis development, and resistance to treatment, its predictive value has so far not been associated with a BC subtype and its mechanisms of action remain understudied.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>To study ER\u03b1-36 expression in BC specimens, we performed immunochemical experiments. Next, the role of ER\u03b1-36 in progesterone signaling was investigated by generating KO clones using the CRISPR\/CAS9 technology. PR signaling was also assessed by proximity ligation assay, Western blotting, RT-QPCR, and ChIP experiments. Finally, proliferation assays were performed with the IncuCyte technology and migration experiments using scratch assays.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Here, we demonstrate that ER\u03b1-36 expression at the plasma membrane is correlated with a reduced disease-free survival in a cohort of 160 BC patients, particularly in PR-positive tumors, suggesting a crosstalk between ER\u03b1-36 and PR. Indeed, we show that ER\u03b1-36 interacts constitutively with PR in the nucleus of tumor cells. Moreover, it regulates PR expression and phosphorylation on key residues, impacting the biological effects of progesterone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>ER\u03b1-36 is thus a regulator of PR signaling, interfering with its transcriptional activity and progesterone-induced anti-proliferative effects as well as migratory capacity. Hence, ER\u03b1-36 may constitute a new prognostic marker as well as a potential target in PR-positive BC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13058-020-01278-7","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T17:10:59Z","timestamp":1589908259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["ER\u03b1-36 regulates progesterone receptor activity in breast cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Henri-Philippe","family":"Konan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleilmane","family":"Omarjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ausra","family":"Surmieliova-Garn\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Jacquemetton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Cascales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Rezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tr\u00e9dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Treilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Poulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Le Romancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"issue":"2","key":"1278_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/ERC-06-0045","volume":"14","author":"RJ Santen","year":"2007","unstructured":"Santen RJ, Boyd NF, Chlebowski RT, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. 2007;14(2):169\u201387.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"1278_CR2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","volume":"9","author":"EA Musgrove","year":"2009","unstructured":"Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631\u201343.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1278_CR3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","volume":"11","author":"A Ring","year":"2004","unstructured":"Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643\u201358.","journal-title":"Endocr Relat Cancer"},{"issue":"23","key":"1278_CR4","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-13-0838","volume":"19","author":"XH Zhang","year":"2013","unstructured":"Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19(23):6389\u201397.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1278_CR5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.bbrc.2005.08.226","volume":"336","author":"Z Wang","year":"2005","unstructured":"Wang Z, Zhang X, Shen P, et al. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005;336(4):1023\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"1278_CR6","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1073\/pnas.0603339103","volume":"103","author":"Z Wang","year":"2006","unstructured":"Wang Z, Zhang X, Shen P, et al. A variant of estrogen receptor-\u03b1, hER-\u03b136: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A. 2006;103(24):9063\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1278_CR7","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1074\/jbc.M111.292946","volume":"287","author":"RA Chaudhri","year":"2012","unstructured":"Chaudhri RA, Olivares-Navarrete R, Cuenca N, et al. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-\u03b136 (ER\u03b136). J Biol Chem. 2012;287(10):7169\u201381.","journal-title":"J Biol Chem"},{"issue":"2","key":"1278_CR8","volume":"5","author":"SL Lin","year":"2010","unstructured":"Lin SL, Yan LY, Zhang XT, et al. ER-\u03b136, a variant of ER-\u03b1, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK\/ERK and PI3K\/Akt pathways. PLoS One. 2010;5(2):e9013.","journal-title":"PLoS One"},{"issue":"11","key":"1278_CR9","volume":"5","author":"JS Tong","year":"2010","unstructured":"Tong JS, Zhang QH, Wang ZB, et al. ER-\u03b136, a novel variant of ER-\u03b1, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta\/ERK pathway. PLoS One. 2010;5(11):e15408.","journal-title":"PLoS One"},{"issue":"18","key":"1278_CR10","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/onc.2016.415","volume":"36","author":"S Omarjee","year":"2017","unstructured":"Omarjee S, Jacquemetton J, Poulard C, et al. The molecular mechanisms underlying the ER\u03b1-36-mediated signaling in breast cancer. Oncogene. 2017;36(18):2503\u201314.","journal-title":"Oncogene"},{"issue":"3","key":"1278_CR11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/cr.2018.15","volume":"28","author":"Q Wang","year":"2018","unstructured":"Wang Q, Jiang J, Ying G, et al. Tamoxifen enhances stemness and promotes metastasis of ER\u03b136(+) breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 2018;28(3):336\u201358.","journal-title":"Cell Res"},{"issue":"Pt B","key":"1278_CR12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jsbmb.2014.08.017","volume":"144","author":"H Deng","year":"2014","unstructured":"Deng H, Yin L, Zhang XT, et al. ER-\u03b1 variant ER-\u03b136 mediates antiestrogen resistance in ER-positive breast cancer stem\/progenitor cells. J Steroid Biochem Mol Biol. 2014;144(Pt B):417\u201326.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"1278_CR13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173931","volume":"12","author":"C Thiebaut","year":"2017","unstructured":"Thiebaut C, Chamard-Jovenin C, Chesnel A, et al. Mammary epithelial cell phenotype disruption in vitro and in vivo through ERalpha36 overexpression. PLoS One. 2017;12(3):e0173931.","journal-title":"PLoS One"},{"issue":"21","key":"1278_CR14","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.2008.17.2254","volume":"27","author":"L Shi","year":"2009","unstructured":"Shi L, Dong B, Li Z, et al. Expression of ER-\u03b136, a novel variant of estrogen receptor \u03b1, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 2009;27(21):3423\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1278_CR15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/nmeth947","volume":"3","author":"O Soderberg","year":"2006","unstructured":"Soderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3(12):995\u20131000.","journal-title":"Nat Methods"},{"issue":"2","key":"1278_CR16","first-page":"99","volume":"28","author":"LM McShane","year":"2006","unstructured":"McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol. 2006;28(2):99\u2013105.","journal-title":"Exp Oncol"},{"issue":"1","key":"1278_CR17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archsurg.1990.01410130113018","volume":"125","author":"DC Allred","year":"1990","unstructured":"Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB Jr. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg. 1990;125(1):107\u201313.","journal-title":"Arch Surg"},{"issue":"2","key":"1278_CR18","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-14-0252","volume":"54","author":"CH Diep","year":"2015","unstructured":"Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 2015;54(2):R31\u201353.","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"1278_CR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2013.11.010","volume":"142","author":"TP Knutson","year":"2014","unstructured":"Knutson TP, Lange CA. Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther. 2014;142(1):114\u201325.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1278_CR20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13058-014-0489-4","volume":"16","author":"N Ogba","year":"2014","unstructured":"Ogba N, Manning NG, Bliesner BS, et al. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast Cancer Res. 2014;16(6):489.","journal-title":"Breast Cancer Res"},{"issue":"50","key":"1278_CR21","doi-asserted-by":"crossref","first-page":"43091","DOI":"10.1074\/jbc.M111.295865","volume":"286","author":"CC Chen","year":"2011","unstructured":"Chen CC, Hardy DB, Mendelson CR. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1\/DUSP1). J Biol Chem. 2011;286(50):43091\u2013102.","journal-title":"J Biol Chem"},{"issue":"7560","key":"1278_CR22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ER\u03b1 action in breast cancer. Nature. 2015;523(7560):313\u20137.","journal-title":"Nature"},{"issue":"17","key":"1278_CR23","doi-asserted-by":"crossref","first-page":"17480","DOI":"10.1074\/jbc.M501261200","volume":"280","author":"ZY Zheng","year":"2005","unstructured":"Zheng ZY, Bay BH, Aw SE, Lin VC. A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. J Biol Chem. 2005;280(17):17480\u20137.","journal-title":"J Biol Chem"},{"issue":"6","key":"1278_CR24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1128\/MCB.23.6.1994-2008.2003","volume":"23","author":"C Ballare","year":"2003","unstructured":"Ballare C, Uhrig M, Bechtold T, et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src\/Erk pathway in mammalian cells. Mol Cell Biol. 2003;23(6):1994\u20132008.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1278_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mce.2011.12.020","volume":"355","author":"DR Cochrane","year":"2012","unstructured":"Cochrane DR, Jacobsen BM, Connaghan KD, et al. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. Mol Cell Endocrinol. 2012;355(1):15\u201324.","journal-title":"Mol Cell Endocrinol"},{"issue":"16","key":"1278_CR26","doi-asserted-by":"crossref","first-page":"25963","DOI":"10.18632\/oncotarget.15657","volume":"8","author":"A Gilam","year":"2017","unstructured":"Gilam A, Shai A, Ashkenazi I, et al. MicroRNA regulation of progesterone receptor in breast cancer. Oncotarget. 2017;8(16):25963\u201376.","journal-title":"Oncotarget"},{"issue":"4","key":"1278_CR27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1210\/me.2013-1196","volume":"28","author":"GE Dressing","year":"2014","unstructured":"Dressing GE, Knutson TP, Schiewer MJ, et al. Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol Endocrinol. 2014;28(4):442\u201357.","journal-title":"Mol Endocrinol"},{"issue":"4","key":"1278_CR28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/me.2007-0437","volume":"22","author":"EJ Faivre","year":"2008","unstructured":"Faivre EJ, Daniel AR, Hillard CJ, Lange CA. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol. 2008;22(4):823\u201337.","journal-title":"Mol Endocrinol"},{"issue":"1\u20132","key":"1278_CR29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mce.2011.09.017","volume":"357","author":"CR Hagan","year":"2012","unstructured":"Hagan CR, Daniel AR, Dressing GE, Lange CA. Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol. 2012;357(1\u20132):43\u20139.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"1278_CR30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc.2016.116","volume":"17","author":"JS Carroll","year":"2017","unstructured":"Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley WD. Deciphering the divergent roles of progestogens in breast cancer. Nat Rev Cancer. 2017;17(1):54\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1278_CR31","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/carcin\/17.9.2069","volume":"17","author":"CM Aldaz","year":"1996","unstructured":"Aldaz CM, Liao QY, LaBate M, Johnston DA. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis. 1996;17(9):2069\u201372.","journal-title":"Carcinogenesis"},{"issue":"11","key":"1278_CR32","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/mend.11.11.0006","volume":"11","author":"SD Groshong","year":"1997","unstructured":"Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11(11):1593\u2013607.","journal-title":"Mol Endocrinol"},{"issue":"4","key":"1278_CR33","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1128\/MCB.18.4.1812","volume":"18","author":"EA Musgrove","year":"1998","unstructured":"Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol. 1998;18(4):1812\u201325.","journal-title":"Mol Cell Biol"},{"issue":"18","key":"1278_CR34","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101426","volume":"38","author":"AS Nacht","year":"2019","unstructured":"Nacht AS, Ferrari R, Zaurin R, et al. C\/EBPalpha mediates the growth inhibitory effect of progestins on breast cancer cells. EMBO J. 2019;38(18):e101426.","journal-title":"EMBO J"},{"issue":"18","key":"1278_CR35","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1158\/0008-5472.CAN-16-3541","volume":"77","author":"J Finlay-Schultz","year":"2017","unstructured":"Finlay-Schultz J, Gillen AE, Brechbuhl HM, et al. Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III. Cancer Res. 2017;77(18):4934\u201346.","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01278-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-020-01278-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01278-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T23:56:49Z","timestamp":1621382209000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01278-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01278-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"16 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}